Jin J Zhou1,2, Daniel S Nuyujukian3,4, Peter D Reaven2,5. 1. Department of Epidemiology and Biostatistics Mel and Enid Zuckerman College of Public Health, University of Arizona, 1295 N. Martin Ave, Tucson, AZ, 85724, USA. 2. Phoenix VA Health Care System, Phoenix, AZ, USA. 3. Department of Epidemiology and Biostatistics Mel and Enid Zuckerman College of Public Health, University of Arizona, 1295 N. Martin Ave, Tucson, AZ, 85724, USA. daniel.nuyujukian@va.gov. 4. Phoenix VA Health Care System, Phoenix, AZ, USA. daniel.nuyujukian@va.gov. 5. College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA.
Abstract
PURPOSE OF REVIEW: There is evidence from epidemiologic studies that variability in cardiovascular risk factors influences risk of cardiovascular disease. We review new studies and novel findings in the relationship between visit-to-visit glycemic variability and blood pressure variability and risk of adverse outcomes. RECENT FINDINGS: Visit-to-visit glycemic variability is consistently linked to macrovascular disease. This relationship has been observed in both clinical trials and retrospective studies of electronic health records. Long-term blood pressure variability also predicts cardiovascular outcomes, and the association appears stronger in those with lower levels of systolic and diastolic function. As epidemiologic evidence increases in support of a role for metabolic risk factor variability in cardiovascular risk, there is a corresponding rise in interest in applying this information toward improving risk factor prediction and treatment. Future investigation of underlying mechanisms for these associations as well as implications for therapy is also warranted. The potential additive contribution of variability of multiple parameters also merits additional scrutiny. As our technology for capturing risk factor variability continues to improve, this will only enhance our understanding of its links with vascular disease and how to best utilize this information to reduce cardiovascular outcomes.
PURPOSE OF REVIEW: There is evidence from epidemiologic studies that variability in cardiovascular risk factors influences risk of cardiovascular disease. We review new studies and novel findings in the relationship between visit-to-visit glycemic variability and blood pressure variability and risk of adverse outcomes. RECENT FINDINGS: Visit-to-visit glycemic variability is consistently linked to macrovascular disease. This relationship has been observed in both clinical trials and retrospective studies of electronic health records. Long-term blood pressure variability also predicts cardiovascular outcomes, and the association appears stronger in those with lower levels of systolic and diastolic function. As epidemiologic evidence increases in support of a role for metabolic risk factor variability in cardiovascular risk, there is a corresponding rise in interest in applying this information toward improving risk factor prediction and treatment. Future investigation of underlying mechanisms for these associations as well as implications for therapy is also warranted. The potential additive contribution of variability of multiple parameters also merits additional scrutiny. As our technology for capturing risk factor variability continues to improve, this will only enhance our understanding of its links with vascular disease and how to best utilize this information to reduce cardiovascular outcomes.
Authors: John W McEvoy; Yuan Chen; Andreea Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin Journal: J Am Coll Cardiol Date: 2016-08-30 Impact factor: 24.094
Authors: Yoichiro Hirakawa; Hisatomi Arima; Sophia Zoungas; Toshiharu Ninomiya; Mark Cooper; Pavel Hamet; Giuseppe Mancia; Neil Poulter; Stephen Harrap; Mark Woodward; John Chalmers Journal: Diabetes Care Date: 2014-05-08 Impact factor: 19.112
Authors: Jonas Ghouse; Morten W Skov; Jørgen K Kanters; Bent Lind; Jonas L Isaksen; Paul Blanche; Stig Haunsø; Lars Køber; Jesper H Svendsen; Morten S Olesen; Anders G Holst; Thomas A Gerds; Jonas B Nielsen Journal: Diabetes Care Date: 2018-10-23 Impact factor: 19.112
Authors: Eric Yuk Fai Wan; Esther Yee Tak Yu; Weng Yee Chin; Florence Ting Yan Ng; Shu Ming Cheryl Chia; Ian Chi Kei Wong; Esther Wai Yin Chan; Cindy Lo Kuen Lam Journal: Diabetes Obes Metab Date: 2020-04-15 Impact factor: 6.577
Authors: John M Lachin; Ionut Bebu; Richard M Bergenstal; Rodica Pop-Busui; F John Service; Bernard Zinman; David M Nathan Journal: Diabetes Care Date: 2017-04-12 Impact factor: 19.112
Authors: Bernard Zinman; Steven P Marso; Neil R Poulter; Scott S Emerson; Thomas R Pieber; Richard E Pratley; Martin Lange; Kirstine Brown-Frandsen; Alan Moses; Ann Marie Ocampo Francisco; Jesper Barner Lekdorf; Kajsa Kvist; John B Buse Journal: Diabetologia Date: 2017-09-15 Impact factor: 10.122
Authors: Juan Zhao; QiPing Feng; Patrick Wu; Roxana A Lupu; Russell A Wilke; Quinn S Wells; Joshua C Denny; Wei-Qi Wei Journal: Sci Rep Date: 2019-01-24 Impact factor: 4.379
Authors: Daniel S Nuyujukian; Michelle S Newell; Jin J Zhou; Juraj Koska; Peter D Reaven Journal: Diabetes Obes Metab Date: 2022-01-24 Impact factor: 6.577